SCTX Insider Cluster Buy: Director Adds to $36M Buying Spree
Behzad Aghazadeh, a Director and 10%+ owner of Scribe Therapeutics, Inc. (SCTX), purchased 7,905 shares of the gene-editing company on July 28, 2026, paying $18.25 per share for a total outlay of $144,266.25. The shares were acquired on the open market, meaning Aghazadeh used personal funds rather than receiving the stock through options or other … Read more